Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Rybelsus is now also indicated for cardiovascular risk reduction in adults with Type 2 diabetes who are at high risk, including those who have not had a prior CV event. This new indication makes ...

Findings showed oral semaglutide statistically significantly reduced the risk of MACE by 14% compared with placebo at 4 years. The Food and Drug Administration (FDA) has approved Rybelsus ® ...

Doctors have long known that antidepressants come with side effects for cardiovascular and metabolic health. But a major analysis from a team of researchers in the U.K. has, for the first time, pulled ...

After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular events (MACE), the FDA has followed suit with a MACE expansion for its ...

The FDA approved Novo Nordisk’s oral semaglutide (Rybelsus) for cardiovascular (CV) risk reduction in adults with type 2 diabetes (T2D) who are at high CV risk, whether or not they’ve had a prior CV ...

The Food and Drug Administration approved Novo Nordisk’s NOVO.B-1.06%decrease; red down pointing triangle oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults ...

The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. The drug, called Rybelsus, is ...

Major advancements in psoriasis treatments in the past two decades have given people living with the autoimmune condition a wide range of options for controlling symptoms. There are more than a dozen ...